Login to Your Account



Other News To Note


Wednesday, May 1, 2013
• CytoDyn Inc., of Lake Oswego, Ore., said it and Drexel University entered a deal with contract development and manufacturing firm Ajinomoto Althea Inc. to formulate CytoDyn's PRO 140 bulk drug substance through a fill-and-finish process for clinical-ready vials to advance two National Institutes of Health (NIH)-funded Phase IIb studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription